Low Grade Glioma clinical trials

Explore recruiting low grade glioma clinical trials.

Recruiting low grade glioma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Low Grade Glioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

Denmark, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluation of diagnostic performances of 18F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliomas : a phase IIIb exploratory trial

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, non-randomized, single dose, phase II trial of FG001 (an optical imaging agent) for localization of Meningiomas or presumed Low- Grade Gliomas scheduled for neurosurgery.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized and controlled phase II protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a newly diagnosed low grade glioma with wild type BRAF gene comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine for 18 months. PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Quality of life and neurocognitive functioning in diffuse low-grade glioma patients treated with Temozolomide: feasibility study - TEMOIN

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

Denmark, Czechia, Austria, Sweden, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Low Grade Glioma trials by city

Low Grade Glioma in Toronto Low Grade Glioma in Vancouver Low Grade Glioma in Montreal Low Grade Glioma in Calgary Low Grade Glioma in Edmonton Low Grade Glioma in Ottawa Low Grade Glioma in Winnipeg Low Grade Glioma in Quebec City Low Grade Glioma in Hamilton Low Grade Glioma in Kitchener Low Grade Glioma in London Low Grade Glioma in Halifax Low Grade Glioma in New York Low Grade Glioma in Los Angeles Low Grade Glioma in Chicago Low Grade Glioma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease